Dr. Lauren Bowen Reoma is the Medical Director of the Intramural NINDS Clinical Trials Unit in the Office of the Clinical Director in Bethesda, MD since 2019. As CTU Medical Director she helps to provide centralized support for NINDS sponsored IND and IDE clinical trials with a focus on regulatory and clinical expertise, serves as the Sponsor’s Medical Monitor for selected NINDS sponsored trials, provides oversight to the Data and Safety Monitoring meetings for trials within intramural NINDS, and supports all work necessary on behalf of intramural NINDS as trial Sponsor for IND, IDE, and abbreviated IDE regulated studies. She is a board-certified neurologist who completed her M.D., Internal Medicine Internship, and Neurology Residency at the University of Florida College of Medicine in from 2007-2015. From 2015-2019, she trained as a Clinical Fellow in the NINDS Neuroimmunology and Neurovirology Program where she completed additional training in Clinical Trials Methodology and the FDA Clinical Investigator Training. She became a Staff Clinician as well as the Medical Director of the Intramural NINDS Clinical Trials Unit in early 2019 in support of clinical trials work within the institute.
Dr. Reoma research focuses on the role of viruses, the immune system, and the interplay between these two within the central nervous system. She completed a clinical research fellowship in the Neuroimmunology and Neurovirology Program at NINDS under Dr. Avindra Nath, from 2015-2019, where she gained an expertise in infections of the central nervous system, neuroimmunology, clinical trials methodology, and oversight of IND-regulated clinical trials. She is a member of the AIDS Clinical Trials Group (ACTG) End-organ Disease, the Inflammation Transformative Science Group and the ACTG Neurology Collaborative Science Group, and American Academy of Neurology. She is the lead investigator on an FDA regulated clinical study NCT03239899: PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection and is an investigator on several intramural studies. She has published in the field of neurovirology and neuroimmunology.
Reoma LB, Trindade CJ, Monaco MC, Solis J, Montojo MG, Vu P, Johnson K, Beck E, Nair G, Khan OI, Quezado M, Hewitt SM, Reich DS, Childs R, Nath A. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol. 2019 Dec;86(6):878-884. doi: 10.1002/ana.25608. Epub 2019 Oct 16. PubMed PMID: 31600832.
Henderson LJ, Reoma LB, Kovacs JA, Nath A. Advances toward Curing HIV-1 Infection in Tissue Reservoirs. J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.00375-19. Print 2020 Jan 17. Review. PubMed PMID: 31694954; PubMed Central PMCID: PMC7000960.
Henderson LJ, Johnson TP, Smith BR, Reoma LB, Santamaria UA, Bachani M, Demarino C, Barclay RA, Snow J, Sacktor N, Mcarthur J, Letendre S, Steiner J, Kashanchi F, Nath A. Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. AIDS. 2019 Dec 1;33 Suppl 2:S145-S157. doi: 10.1097/QAD.0000000000002268. PubMed PMID: 31789815.
Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019 Apr 25;380(17):1597-1605. doi: 10.1056/NEJMoa1815039. Epub 2019 Apr 10. PubMed PMID: 30969503.
Bowen LN, Smith B, Reich D, Quezado M, Nath A. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol. 2016 Oct 27;12(11):662-674. doi: 10.1038/nrneurol.2016.149. Review. PubMed PMID: 27786246.
Gatti-Mays ME, Manion M, Bowen LN, Brown GT, Danner RL, Khan O, Nath A, Battiwalla M, Barrett AJ, Ito S. Toxoplasmosis encephalitis with immune-reconstitution inflammatory syndrome in an allogeneic stem cell transplant patient: a case report. Bone Marrow Transplant. 2016 Dec;51(12):1622-1624. doi: 10.1038/bmt.2016.230. Epub 2016 Sep 19. PubMed PMID: 27643867.
Bowen LN, Tyagi R, Li W, Alfahad T, Smith B, Wright M, Singer EJ, Nath A. HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. Neurology. 2016 Oct 25;87(17):1756-1762. doi: 10.1212/WNL.0000000000003258. Epub 2016 Sep 24. PubMed PMID: 27664983; PubMed Central PMCID: PMC5089528.
Link to publications: https://www.ncbi.nlm.nih.gov/myncbi/lauren.bowen.1/bibliography/public/